


Product Description

Product Name:	LV-DRD2-PGK-Puro
Catalog Number:	LV027-S (0.25 mL), LV027-L (1 mL)
Lot Number:	LV-IM9
Reporter gene:	Human Dopamine Receptor D2 (DRD2)
Promoter:	Spleen focus-forming virus (SFFV)
Selection gene:	Puromycin (Puro)
Quantity:	250 μ L (S) or 1 mL (L)
Titer:	2.54 x 10 ⁷ TU/mL*
Storage media:	Serum free media
Shipping: Storage: Shelf life:	Dry ice Store at \leq -70°C upon receipt. Freeze-thaw cycles will decrease titer. One year from date of receipt under proper
	storage conditions.

This is a ready-to-use lentivirus preparation. The virus encodes the human dopamine receptor D2 (DRD2) cDNA under control of the spleen focus-forming virus (SFFV) promoter and the puromycin resistance gene (puro) under the phosphoglycerate kinase (PGK) promoter (see below). The lentiviral vectors are selfinactivating (SIN) vectors in which the viral enhancer and promoter have been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without *cis*-acting effects of the LTR¹.



5' LTR: 5' long terminal repeat ψ: RNA packaging signal RRE: Rev response element cPPT: Central polypurine tract SFFV: Spleen focus-forming virus promoter DRD2: Human dopamine receptor D2 PGK: phosphoglycerate kinase promoter Puro: puromycin resistance gene WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element 3' LTR/ΔU3: 3' self-inactivating long terminal repeat

*Titration by qPCR:

A WPRE probe-based qPCR assay was used to measure the number of copies of lentiviruses stably integrated into the genome after transduction of HeLa H1 cells (transducing units per mL).

Traditional p24 ELISA titrations measure both functional and nonfunctional lentivirus particles. However, this method overestimates the functional titer, as the p24 protein pool includes a variable amount of free p24 and p24 associated with non-functional vector particles. This ratio can vary greatly between each lot, so the titration is inherently inaccurate. While qPCR titers may appear lower than p24 ELISA, they are more accurate and functional.

Safety Precaution:

All culture work with lentiviruses should be performed by trained personnel and performed under BSL2 containment following NIH guidelines.



Basic Lentivirus Transduction Protocol

Volumes are given for a 6-well plate; increase or decrease as needed. See the Transduction Tips section for additional considerations/modifications.

- 1. Seed cells in complete medium at an appropriate density to achieve 60-70% confluency the next day (e.g. $\sim 2.5 \times 10^5$ HeLaH1 cells). Incubate cells overnight in a 37°C/5% CO₂ incubator.
- 2. Thaw lentivirus stock on ice.
- 3. In a microcentrifuge tube, dilute lentivirus to 1 mL total in serum free media. (See tips below for notes about determining optimal MOIs.)
- 4. Remove culture medium from cells and replace with prepared lentivirus.
- 5. Return cells to 37°C/5% CO₂ incubator.
- 6. After 4 hours add 1 mL complete medium to each well and return cells to $37^{\circ}C/5\%$ CO₂ incubator.
- 7. 3-7 days after transduction, check transgene expression according to an appropriate protocol. (Note: this lentivirus includes a selection gene; see tips below for details.)

Transduction Tips

- 1. To determine the optimal MOI for transductions: plate several wells of the target cells and infect with increasing MOIs (e.g 1, 3, 10, and 30). Typically, primary cells require higher MOIs than established cell lines.
- <u>Polybrene[®]</u> (Imanis #REA001) can be added to the transduction mixture to enhance transduction efficiency². The final concentration of Polybrene[®] in the transduction medium should be 4-8 µg/mL. *Polybrene[®] can be cytotoxic to some cells and it is not advisable to incubate these cells with Polybrene[®] overnight; the transduction cocktail may be removed after 3-4 h and replaced with complete media.*
- 3. A spin infection can also be used to increase transduction efficiency³. Once the transduction mixture is added to the cells, centrifuge the plate at 800 x g for 30 min at room temperature, before placing the cells in a $37^{\circ}C/5\%CO_2$ incubator.
- 4. The presence of serum in the transduction mixture can greatly affect transduction efficiency⁴. In general, lower serum concentrations result in higher transduction efficiencies, though optimizing serum concentrations is recommended for each cell type.
- 5. The presence of the puromycin resistance gene facilitates selection of transduced cells with puromycin. Selection with puromycin can be performed before or after transgene testing. The appropriate concentration of puromycin to use for selection varies with each cell line and can be determined by performing a kill curve on parental in parallel with transduced cells.

References

¹Miyoshi et al. J Virol. 1998. 72:8150-8157.
²Konopka et al. J Gen Virol 1991. 72: 2685-2696.
³O'Doherty et al. J Virol. 2000. 74:10074-10080.
⁴Andreadis and Palsson. Human Gene Ther. 1997. 8:285-291.
⁵MacLaren et al. Gene Ther. 1999. 6:785-791.




Certificate of Analysis

Testing performed by Imanis Life Sciences

Test description	Result
Virus titer	2.54 x 10 ⁷ TU/mL
Sterility	No contamination detected
Puromycin selection	Pass QC
DRD2 expression	Pass QC
Endotoxin testing	Pass QC

Dopamine Receptor D2 Expression:



HeLaH1 cells were transduced with LV-DRD2-PGK-Puro (MOI = 2) and after three days the cells were amplified under puromycin selection. Transduced cells (red) and untransduced control cells (grey) were labeled with a spiperone derivative (dopamine receptor D2 antagonist) coupled to a red fluorescent probe. After binding, cells were fixed with paraformaldehyde and analyzed by flow cytometry.

Legal Disclaimers

Limited Product Warranty

This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including, without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Imanis. Imanis shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

For in vitro use only. This certificate is a declaration of analysis at the time of manufacture.

PURCHASER NOTIFICATION

LIMITED LICENSE NOTICE - RESEARCH USE ONLY

IMANIS LIFE SCIENCES HAS A LIMTED LICENSE UNDER PATENTS OWNED BY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES THAT PERMITS IMANIS LIFE SCIENCES TO SELL PRODUCTS CONTAINING WPRE FOR RESEARCH USE ONLY AND NOT FOR ANY COMMERCIAL USES. EXCLUDED COMMERCIAL USES INCLUDE WITHOUT LIMITATION MANUFACTURING, PROVIDING A SERVICE, THERAPEUTIC, DIAGNOSTIC AND PROPHYLACTIC USES, AND ANY OTHER COMMERCIAL USES. USE OF THIS PRODUCT BY A PURCHASER FOR ANY PURPOSE OTHER THAN FOR RESEARCH IS UNAUTHORIZED AND PROHIBITED.

The Salk Institute actively licenses its patents for commercial uses, and a commercial use license may be available for Salk's WPRE patents. If you wish to inquire about such a license, please contact:

Office of Technology Development The Salk Institute for Biological Studies 10010 North Torrey Pines Road La Jolla, CA 92037 Phone: (858) 453-4100 extension 1278 Fax: (858) 546-8093

Quality control by: RLV/JKM Quality Assurance by: LS Effective Date: 27-Sept-2016